Department of Population Medicine and Diagnostic Sciences, Cornell University, Ithaca, NY 14853-6401.
Department of Population Medicine and Diagnostic Sciences, Cornell University, Ithaca, NY 14853-6401.
J Dairy Sci. 2021 Mar;104(3):3364-3385. doi: 10.3168/jds.2020-18830. Epub 2020 Dec 25.
The general objective of this study was to evaluate the effect of 3 intramammary antibiotic interventions using 2 commercially available antibiotics with narrow- or broad-spectrum activity on cure rates of clinical mastitis (CM) caused by gram-positive bacteria. We also compared the efficacy of treatment protocols, including a negative control, on outcomes at the cow and mammary quarter level. Before the onset of the study, 5,987 animals more than 12 mo old were randomly preassigned to 1 of 4 protocols in the event of gram-positive CM (except for Staphylococcus aureus and Trueperella pyogenes) during lactation: 3 infusions with 62.5 mg of amoxicillin performed 12 h apart (AMOX-L); 5 infusions once a day with 62.5 mg of amoxicillin (AMOX-EL); 5 infusions once a day with 125 mg of ceftiofur hydrochloride (CEFT-L); or negative control, no treatment performed until 5 d after diagnosis (NEG-CTR). Randomization was performed to preassign 90% of cows to one of the antibiotic protocols (30% in each group) and 10% to the negative control. A total of 696 quarter cases of CM met the inclusion criteria and were evaluated in the study. Quarter-level outcomes were assessed based on 5 milk samples collected up to 14 ± 3 d following enrollment (i.e., first day of treatment), whereas variables at the cow level [composite somatic cell count (SCC), milk production, and survival in the herd] were assessed up to 90 d after CM diagnosis. Streptococcus uberis, followed by Streptococcus dysgalactiae, were the main causes of gram-positive CM. Overall, clinical cure was higher for CEFT-L than for AMOX-EL, and no difference was observed between CEFT-L and AMOX-L. Likewise, no significant differences were detected on overall bacteriological cure, although some treatment effects were observed at the species level. Compared with antibiotic-treated groups, quarters assigned to NEG-CTR had higher counts of colony-forming units (cfu), 16S rRNA gene copy numbers, and Streptococcus relative abundance (RA) until d 5 after enrollment. Quarters treated with AMOX-L had higher cfu counts on d 5, 8, and 14 after enrollment compared with the other antibiotic protocols. In addition, the RA of Streptococcus spp. was higher on d 14 after enrollment for AMOX-treated quarters compared with the CEFT-L group. Linear score of SCC was higher for AMOX-treated cows than for CEFT-L in the first test day after CM. However, cows assigned to AMOX-L had higher milk production than those submitted to the AMOX-EL and CEFT-L protocols. In conclusion, the 2-d protocol with 3 intramammary infusions of amoxicillin (narrow-spectrum antimicrobial) had similar overall clinical and bacteriological cures as 5 administrations (once a day) with ceftiofur hydrochloride (wide spectrum). No significant difference was observed on CM recurrence and cow survival. However, quarters treated with 5-d protocols were more effective at reducing milk cfu counts than quarters in the AMOX-L protocol. In addition, lower Streptococcus spp. RA was observed in ceftiofur-treated quarters compared with the amoxicillin protocols at d 14 after CM diagnosis. Based on results of microbiome and bacterial load (quantitative PCR and cfu count) up to 5 d after CM diagnosis, antibiotic use remains an indispensable strategy for treatment of CM caused by gram-positive bacteria.
本研究的总体目标是评估 3 种使用具有窄谱或广谱活性的 2 种市售抗生素进行的乳房内抗生素干预对由革兰氏阳性菌引起的临床乳腺炎(CM)治愈率的影响。我们还比较了包括阴性对照在内的治疗方案的疗效,以评估奶牛和乳房 quarters 水平的结果。在研究开始前,随机将 5987 头年龄超过 12 个月的动物分配到 4 种方案中的 1 种,以防在哺乳期发生革兰氏阳性 CM(金黄色葡萄球菌和 Trueperella pyogenes 除外):每隔 12 小时进行 3 次 62.5mg 阿莫西林输注(AMOX-L);每天 5 次输注 62.5mg 阿莫西林(AMOX-EL);每天 1 次输注 125mg 头孢噻呋盐酸盐(CEFT-L);或阴性对照,在诊断后 5 天内不进行治疗(NEG-CTR)。随机化将 90%的奶牛分配到一种抗生素方案中(每组 30%),10%的奶牛分配到阴性对照组。共有 696 个 CM 乳房 quarters 符合纳入标准并纳入研究。乳房 quarters 水平的结果是基于在入组后 14 ± 3 天(即治疗的第一天)采集的 5 个牛奶样本进行评估的,而奶牛水平的变量[复合体细胞计数(SCC)、牛奶产量和在畜群中的存活情况]则是在 CM 诊断后 90 天进行评估的。无乳链球菌,其次是停乳链球菌,是革兰氏阳性 CM 的主要原因。总的来说,CEFT-L 的临床治愈率高于 AMOX-EL,CEFT-L 与 AMOX-L 之间没有差异。同样,虽然在物种水平上观察到了一些治疗效果,但在整体细菌学治愈率方面没有观察到显著差异。与接受抗生素治疗的组相比,在入组后第 5 天,NEG-CTR 组的菌落形成单位(cfu)、16S rRNA 基因拷贝数和链球菌相对丰度(RA)更高。与其他抗生素方案相比,接受 AMOX-L 治疗的 quarters 在入组后第 5、8 和 14 天的 cfu 计数更高。此外,与 CEFT-L 组相比,在入组后第 14 天,接受 AMOX 治疗的 quarters 链球菌属的 RA 更高。在 CM 后第一次测试日,接受 AMOX 治疗的奶牛的 SCC 线性评分高于接受 CEFT-L 的奶牛。然而,与 AMOX-EL 和 CEFT-L 方案相比,接受 AMOX-L 治疗的奶牛的牛奶产量更高。综上所述,与 5 次(每天 1 次)头孢噻呋盐酸盐(广谱)相比,3 次乳房内注射阿莫西林(窄谱抗菌药物)的 2 天方案在整体临床和细菌学治愈率方面相似。CM 复发和奶牛存活率无显著差异。然而,与 AMOX-L 方案相比,接受 5 天方案治疗的 quarters 降低牛奶 cfu 计数的效果更好。此外,与 AMOX 治疗方案相比,在 CM 诊断后第 14 天,头孢噻呋治疗的 quarters 链球菌属的 RA 较低。基于 CM 诊断后 5 天的微生物组和细菌负荷(定量 PCR 和 cfu 计数)的结果,抗生素的使用仍然是治疗革兰氏阳性菌引起的 CM 的不可或缺的策略。